Shares of AnaptysBio Inc (NASDAQ: ANAB) surged 5.13% in pre-market trading on Monday, as the biotechnology company gained traction ahead of its upcoming quarterly earnings report. The rise was fueled by optimistic analyst expectations and positive sentiment surrounding the company's prospects.

According to an earnings preview, analysts are forecasting AnaptysBio to report a loss of $1.59 per share for the quarter. However, the consensus estimate has risen by nearly 6% over the past three months, indicating growing confidence in the company's performance. Despite the projected loss, Wall Street's median 12-month price target for ANAB stands at $48.50, well above its last closing price of $19.88.

Notably, H.C. Wainwright lowered its price target on AnaptysBio to $52 from $55 but maintained a "Buy" rating on the stock, suggesting the firm remains bullish on the company's long-term outlook. Meanwhile, Leerink Partners also trimmed its target to $45, though this still implies substantial upside potential from current levels.